Esperion Therapeutics, Inc.
General ticker "ESPR" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $367.2M (TTM average)
Esperion Therapeutics, Inc. follows the US Stock Market performance with the rate: 58.5%.
Estimated limits based on current volatility of 4.1%: low 2.68$, high 2.91$
Factors to consider:
- Total employees count: 304 (+26.7%) as of 2024
- Top business risk factors: Dependence on two products, Regulatory and compliance, Senior management dependency, Liquidity and credit risks, Operational and conduct risks
- Current price 22.3% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.97$, 2.91$]
- 2025-12-31 to 2026-12-31 estimated range: [0.70$, 2.22$]
Financial Metrics affecting the ESPR estimates:
- Positive: with PPE of 56.2 at the end of fiscal year the price was very low
- Negative: Operating cash flow per share per price, % of -5.62 <= 0.01
- Positive: 7.67 < Operating profit margin, % of 16.37
- Negative: Shareholder equity ratio, % of -113.06 <= 19.40
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: negative Industry operating income (median)
- Positive: Inventory ratio change, % of -5.14 <= -0.75
Short-term ESPR quotes
Long-term ESPR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $75.47MM | $116.33MM | $332.31MM |
| Operating Expenses | $254.98MM | $271.90MM | $277.91MM |
| Operating Income | $-179.50MM | $-155.56MM | $54.40MM |
| Non-Operating Income | $-54.16MM | $-53.69MM | $-106.15MM |
| Interest Expense | $56.81MM | $58.98MM | $59.25MM |
| R&D Expense | $118.93MM | $86.11MM | $46.24MM |
| Income(Loss) | $-233.66MM | $-209.25MM | $-51.74MM |
| Profit(Loss)* | $-233.66MM | $-209.25MM | $-51.74MM |
| Stockholders Equity | $-323.78MM | $-454.99MM | $-388.72MM |
| Inventory | $35.20MM | $65.62MM | $94.49MM |
| Assets | $247.94MM | $205.80MM | $343.82MM |
| Operating Cash Flow | $-174.83MM | $-135.49MM | $-23.65MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.32MM |
| Investing Cash Flow | $8.10MM | $42.50MM | $-0.32MM |
| Financing Cash Flow | $32.61MM | $50.46MM | $86.48MM |
| Earnings Per Share** | $-3.52 | $-2.03 | $-0.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.